Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis
The DOI matches its Crossref record, with a small difference in title or year; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Background: Several pharmacologic options for type 2 diabetes are available. Purpose: To compare benefits and harms of glucose-lowering drugs in adults with type 2 diabetes. Data Sources: Several databases from inception through 18 December 2019 and ClinicalTrials.gov on 10 April 2020. Study Selection: English-language randomized trials that had at least 24 weeks of intervention and assessed the effects of glucose-lowering drugs on mortality, glycemic, and vascular outcomes. Data Extraction: Pairs of reviewers extracted data and appraised risk of bias. Data Synthesis: 453 trials assessing 21 antidiabetic interventions from 9 drug classes were included. Interventions included monotherapies (134 trials), add-on to metformin-based therapies (296 trials), and monotherapies versus add-on to metformin therapies (23 trials). There were no differences between treatments in drug-naive patients at low cardiovascular risk. Insulin regimens and specific glucagon-like peptide-1 receptor agonists (GLP-1 RAs) added to metformin-based background therapy produced the greatest reductions in hemoglobin A1c level. In patients at low cardiovascular risk receiving metformin-based background treatment (298 trials), there were no clinically meaningful differences between treatments for mortality and vascular outcomes. In patients at increased cardiovascular risk receiving metformin-based background treatment (21 trials), oral semaglutide, empagliflozin, liraglutide, extended-release exenatide, and dapagliflozin reduced all-cause mortality. Oral semaglutide, empagliflozin, and liraglutide also reduced cardiovascular death. Odds of stroke were lower with subcutaneous semaglutide and dulaglutide. Sodium–glucose cotransporter-2 (SGLT-2) inhibitors reduced heart failure hospitalization and end-stage renal disease. Subcutaneous semaglutide and canagliflozin increased diabetic retinopathy and amputation, respectively. Limitation: Inconsistent definitions of cardiovascular risk and low-level confidence in some estimates for patients at low cardiovascular risk. Conclusion: In diabetic patients at low cardiovascular risk, no treatment differs from placebo for vascular outcomes. In patients at increased cardiovascular risk receiving metformin-based background therapy, specific GLP-1 RAs and SGLT-2 inhibitors have a favorable effect on certain cardiovascular outcomes. Primary Funding Source: European Foundation for the Study of Diabetes, supported by an unrestricted educational grant from AstraZeneca. (PROSPERO: CRD42019122043)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a network meta-analysis of 453 trials assessing glucose-lowering medications from nine drug classes, the greatest reductions in HbA1c were seen with insulin regimens and GLP-1 RA (223).”
In the citing paper
“However, the comparative effectiveness of the two drug classes has been assessed in three recent network meta-analyses, which found that, in people with type 2 diabetes, SGLT2i were superior to GLP-1 RA in reducing HHF and a composite kidney outcome, while GLP-1 RA seemed more ef fi cacious in reducing the risk of stroke (223,259,260).”
In the citing paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
In the citing paper
“In a large systemic review and network analysis, including several GLP-1RAs, subcutaneous semaglutide was the only glucose-lowering drug for which this signal was observed”
From Safety of Semaglutide (2021) · cites this paper as [120]
In the citing paper
“A systematic review and meta-analysis of CGM use in adults with type 2 diabetes (12 randomized clinical trials with 1248 participants taking insulin, GLP-1RA, or oral glucose-lowering medications) reported that CGM led to a mean difference in HbA1C reduction over 10 to 34 weeks of −0.31% (95% CI, −0.43% to −0.19%) compared with BGM.49”
From Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review (2025) · cites this paper as [49]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269 · cited 1×
“ods (9), and report detailed methods in section 1 of the Supplement (available at Annals.”
MethodDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · cited 1×
“On the basis of pairwise meta-analyses of cardiovascular outcome trials, compared with placebo, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce cardiovascular death and stroke (4), whereas sodium–glucose cotransporter-2 (SGLT-2) inhibitors reduce heart failure hospitalization (5) and end-stage renal disea…”
BackgroundChecking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521 · cited 1×
“We evaluated consistency in the networks both locally by comparing direct with indirect evidence (19) and globally by using the design-by-treatment interaction model (20).”
MethodConsistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
Higgins, J. P. T., Jackson, D., Barrett, J. K., Lu, G., Ades, A. E., & White, I. R. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1044 · Cited by 2,098 · cited 1×
“We evaluated consistency in the networks both locally by comparing direct with indirect evidence (19) and globally by using the design-by-treatment interaction model (20).”
MethodOral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
CINeMA: an approach for assessing confidence in the results of a network meta-analysis
Nikolakopoulou, A., Higgins, J. P. T., Papakonstantinou, T., Chaimani, A., Del Giovane, C., Egger, M., & Salanti, G. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003082 · Cited by 1,935
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 1×
“On the basis of pairwise meta-analyses of cardiovascular outcome trials, compared with placebo, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce cardiovascular death and stroke (4), whereas sodium–glucose cotransporter-2 (SGLT-2) inhibitors reduce heart failure hospitalization (5) and end-stage renal disea…”
BackgroundBuse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Conceptual and technical challenges in network meta-analysis
Cipriani, A., Higgins, J. P. T., Geddes, J. R., & Salanti, G. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-2-201307160-00008 · Cited by 1,072 · cited 1×
“Data Synthesis and Analysis Initially, we did pairwise meta-analyses and then explored the transitivity assumption that a network meta-analysis approach was appropriate by comparing the distribution of potential effect modifiers across treatment comparisons (duration of diabetes, age, hemoglobin A1c level at baseline,…”
Method9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
Neuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30256-6 · Cited by 893 · cited 1×
“On the basis of pairwise meta-analyses of cardiovascular outcome trials, compared with placebo, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce cardiovascular death and stroke (4), whereas sodium–glucose cotransporter-2 (SGLT-2) inhibitors reduce heart failure hospitalization (5) and end-stage renal disea…”
BackgroundTurner, R. M., Davey, J., Clarke, M. J., Thompson, S. G., & Higgins, J. P. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dys041 · Cited by 837 · cited 1×
“We evaluated heterogeneity by comparing the magnitude of the common between-study variance ( (2)) for each outcome with empirical distributions of heterogeneity variances (17, 18).”
MethodZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781
Network meta‐analysis, electrical networks and graph theory
Rücker, G. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1058 · Cited by 730
Chaimani, A., & Salanti, G. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.57 · Cited by 521 · cited 1×
“The presence of small-study effects bias was assessed by means of comparison-adjusted funnel plots (21).”
MethodPalmer, S. C., Mavridis, D., Nicolucci, A., Johnson, D. W., Tonelli, M., Craig, J. C., Maggo, J., Gray, V., De Berardis, G., Ruospo, M., et al. (2016) · JAMA · doi:10.1001/jama.2016.9400 · Cited by 420
Zheng, S. L., Roddick, A. J., Aghar-Jaffar, R., Shun-Shin, M. J., Francis, D., Oliver, N., & Meeran, K. (2018) · JAMA · doi:10.1001/jama.2018.3024 · Cited by 403
Rhodes, K. M., Turner, R. M., & Higgins, J. P. T. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2014.08.012 · Cited by 395
Cefalu, W. T., Kaul, S., Gerstein, H. C., Holman, R. R., Zinman, B., Skyler, J. S., Green, J. B., Buse, J. B., Inzucchi, S. E., Leiter, L. A., et al. (2018) · Diabetes Care · doi:10.2337/dci17-0057 · Cited by 363
Rücker, G., & Schwarzer, G. (2014) · Statistics in Medicine · doi:10.1002/sim.6236 · Cited by 217
Brignardello-Petersen, R., Murad, M. H., Walter, S. D., McLeod, S., Carrasco-Labra, A., Rochwerg, B., Schünemann, H. J., Tomlinson, G., & Guyatt, G. H. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2018.08.022 · Cited by 173
The relation between treatment benefit and underlying risk in meta-analysis
Sharp, S. J., Thompson, S. G., & Altman, D. G. (1996) · BMJ · doi:10.1136/bmj.313.7059.735 · Cited by 172
Zhu, J., Yu, X., Zheng, Y., Li, J., Wang, Y., Lin, Y., He, Z., Zhao, W., Chen, C., Qiu, K., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30422-x · Cited by 160
Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
Fei, Y., Tsoi, M.-F., & Cheung, B. M. Y. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0916-z · Cited by 156
Network meta-analysis: a norm for comparative effectiveness?
Higgins, J. P. T., & Welton, N. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61478-7 · Cited by 133
Hussein, H., Zaccardi, F., Khunti, K., Davies, M. J., Patsko, E., Dhalwani, N. N., Kloecker, D. E., Ioannidou, E., & Gray, L. J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14008 · Cited by 82
Tang, H., Li, G., Zhao, Y., Wang, F., Gower, E. W., Shi, L., & Wang, T. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13232 · Cited by 78
Jia, Y., Lao, Y., Zhu, H., Li, N., & Leung, S.-W. (2018) · Obesity Reviews · doi:10.1111/obr.12753 · Cited by 67
Karagiannis, T., Avgerinos, I., Toumpalidou, M., Liakos, A., Kitsios, K., Dimitriadis, G., Παπάνας, Ν., Bargiota, Α., Avramidis, I., Katsoula, A., et al. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05608-0 · Cited by 16
Self-citation
Research works printed but not linked: 1
- Schwarzer G, 2007, R news, 7, 40
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
“A recent systematic review and network meta-analysis suggests greatest reductions in A1C level with insulin regimens and specific GLP-1 RAs added to metformin-based background therapy (60).”
BackgroundDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
Metadata
- Authors
- Tsapas, A., Avgerinos, I., Karagiannis, T., Malandris, K., Manolopoulos, A., Andreadis, P., Liakos, A., Matthews, D. R., & Bekiari, E.
- Affiliations
- Clinical Research and Evidence-Based Medicine Unit and Diabetes Centre, Aristotle University of Thessaloniki, Thessaloniki, Greece, and Harris Manchester College, University of Oxford, Oxford, United Kingdom (A.T.)
- Aristotle University of Thessaloniki (GR)
- Churchill Hospital (GB)
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2020-08-18
- Volume
- 173
- Issue
- 4
- Pages
- 278-286
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W3037508799
- Cited by
- 346
- References
- 34
- Citations by year
- 2026: 31 · 2025: 62 · 2024: 75 · 2023: 67 · 2022: 51 · 2021: 50 · 2020: 10
- FWCI
- 33.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Foundation for the Study of Diabetes (PAtient-Centred Treatment to support a holistic approach towards type 2 diabetes (PACT) Programme supported by an unrestricted educational grant from AstraZeneca)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, antidiabetic drugs, comparative effectiveness, metformin, GLP-1 receptor agonists, SGLT2 inhibitors, semaglutide, empagliflozin, liraglutide, dapagliflozin, canagliflozin, insulin, cardiovascular risk, all-cause mortality, cardiovascular mortality, stroke, heart failure hospitalization, end-stage renal disease, diabetic retinopathy, amputation, glycemic control, HbA1c, vascular outcomes, risk of bias
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.